Outsourced Pharma Capability Update – Cell Line Development June 2026

Early cell line decisions define everything that comes after: yield, stability, manufacturability, and timelines. That’s why we presented at the Outsourced Pharma Capabilities Update on June 16th, which is focused on Cell Line Development strategies.

Abzena’s VP & Scientific Leader of Cell Line Development, John E. Gill IV, presented a talk on “Integrated Cell Line Development: Manufacturability to GMP-Ready by Design.” John broke down how a truly integrated approach, one built with GMP readiness and manufacturability in mind from day one, changes the trajectory of complex biologic programs.

The result:
– Accelerated timelines to GMP
– Reduced downstream risk
– Cell lines engineered to meet GMP standards, not retrofitted to them
– A smoother, faster path from discovery to clinical & commercial manufacturing

When GMP readiness is designed in from the start, not added later, programs don’t stall. They move forward faster.

Access the On-Demand Recording